Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the end of this year after the company gained the Hong Kong government approval to sell the drug in a device called Kwikpen for both long-term weight management and type 2 diabetes, the company said in a statement to Bloomberg News. The launch will potentially make Mounjaro the first weight loss drug of its kind to become available in the China region, Bloomberg stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly, ViaNautis sign collaboration agreement for polyNaut platform
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024
- Apogee Therapeutics price target raised to $100 from $81 at BTIG
- Eli Lilly’s Weight Loss Drug Mounjaro Finds its Place in Hong Kong
- Eli Lilly announces results from two, multi-year mirikizumab studies